RESUMEN
α2 -Adrenoceptor agonists such as clonidine and dexmedetomidine are used as adjuvants to local anesthetics in regional anesthesia. Fadolmidine is an α2 -adrenoceptor agonist developed especially as a spinal analgesic. The current studies investigate the effects of intrathecally administered fadolmidine with a local anesthetic, bupivacaine, on antinociception and motor block in conscious rats and dogs. The antinociceptive effects of intrathecal fadolmidine and bupivacaine alone or in combination were tested in the rat tail-flick and the dog's skin twitch models. The durations of motor block in rats and in dogs were also assessed. In addition, the effects on sedation, mean arterial blood pressure, heart rate, respiratory rate and body temperature were evaluated in telemetrized dogs. Concentrations of fadolmidine in plasma and spinal cord were determined after intrathecal and intravenous administration in rats. Co-administration of intrathecal fadolmidine with bupivacaine increased the magnitude and duration of the antinociceptive effects and prolonged motor block without hypotension. The interaction of the antinociceptive effect was synergistic in its nature in rats. Concentration of fadolmidine in plasma was very low after intrathecal dosing. Taken together, these studies show that fadolmidine as an adjuvant to intrathecal bupivacaine provides enhanced sensory-motor block and enables a reduction of the doses of both drugs. The results indicate that co-administration of fadolmidine with intrathecal bupivacaine was able to achieve an enhanced antinociceptive effect without hypotension and could thus represent a suitable combination for spinal anesthesia.
Asunto(s)
Adyuvantes Anestésicos/administración & dosificación , Agonistas de Receptores Adrenérgicos alfa 2/administración & dosificación , Analgésicos/administración & dosificación , Anestesia Raquidea , Anestésicos Locales , Bupivacaína , Imidazoles/administración & dosificación , Indanos/administración & dosificación , Adyuvantes Anestésicos/sangre , Adyuvantes Anestésicos/farmacocinética , Agonistas de Receptores Adrenérgicos alfa 2/sangre , Agonistas de Receptores Adrenérgicos alfa 2/farmacocinética , Analgésicos/sangre , Analgésicos/farmacocinética , Animales , Presión Arterial/efectos de los fármacos , Temperatura Corporal/efectos de los fármacos , Perros , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Imidazoles/sangre , Imidazoles/farmacocinética , Indanos/sangre , Indanos/farmacocinética , Masculino , Ratas Sprague-Dawley , Frecuencia Respiratoria/efectos de los fármacos , Prueba de Desempeño de Rotación con Aceleración Constante , Médula Espinal/metabolismoRESUMEN
AIM: Gamma-hydroxybutyrate (GHB) is a common drug of abuse with an elimination half-life of 20-45 min. However, there is some evidence that GHB might exhibit saturation kinetics after ingesting high recreational doses. The aim of this study was to investigate the elimination kinetics of GHB from blood in people apprehended by the police for impaired driving and secondary to describe concentrations in all GHB-positive drivers. METHODS: Two consecutive blood samples were taken about 30-40 min apart from N = 16 apprehended drivers in Norway. GHB was determined in blood by an Ultra High-Performance Liquid Chromatography-Tandem Mass Spectrometry (UHPLC-MS/MS) method. The changes in GHB between the two consecutive blood samples allowed estimating GHB's elimination half-life, assuming first-order and zero-order elimination kinetics. GHB concentrations are also reported for N = 1276 apprehended drivers with GHB in blood. RESULTS: The median time interval between collecting the two blood samples was 36 min (range 20-56 min). The median concentration of GHB in the first blood sample was 56.5 mg/L (range 14.1-142 mg/L) compared with 47.8 mg/L in the second sample (range 9.75-113 mg/L). The median elimination half-life was 103 min (range 21-187 min), and GHB's median zero-order elimination rate constant was 21.0 mg/L/h (range 6.71-45.4 mg/L/h). Back-calculation to the time of driving resulted in GHB concentrations up to 820 mg/L assuming first-order kinetics and up to 242 mg/L assuming zero-order kinetics. In all drivers (N = 1276), the median GHB concentration was 73.7 mg/L and highest was 484 mg/L. CONCLUSION: The elimination half-life of GHB in blood samples from apprehended drivers was longer than expected compared with results of controlled dosing studies. Zero-order kinetics seems a more appropriate model for GHB when concentrations are back-calculated, and the median elimination rate was 21 mg/L/h.
Asunto(s)
Adyuvantes Anestésicos/farmacocinética , Conducir bajo la Influencia , Oxibato de Sodio/farmacocinética , Adyuvantes Anestésicos/sangre , Cromatografía Líquida de Alta Presión , Toxicología Forense , Semivida , Humanos , Noruega , Oxibato de Sodio/sangre , Detección de Abuso de Sustancias , Espectrometría de Masas en TándemRESUMEN
PURPOSE: To determine the quantity of dexamethasone plasma concentration achieved following intrapterygomandibular space injection of dexamethasone when co-administered with inferior alveolar nerve block correlating with the clinical effects in the postoperative phase. OBJECTIVE: A preliminary prospective study to evaluate the dexamethasone plasma concentration achieved following intrapterygomandibular space injection of dexamethasone with 2% lignocaine inferior alveolar nerve block to achieve hemi-mandibular anesthesia for minor oral surgical procedures and derive clinical correlations. BACKGROUND: Dexamethasone is a glucocorticoid, chiefly used for the management of postsurgical sequelae like trismus and swelling in maxillofacial surgical practice. Conventionally, parenteral dexamethasone is administered via intravenous or intramuscular route. Intrapterygomandibular space injection is a novel route of steroid delivery described in literature. For minor oral surgical procedures in maxillofacial surgical practice requiring inferior alveolar nerve block, dexamethasone can be administered along with local anesthetic through a single injection as a mixture (twin mix). METHODS: Prospective double-blind randomized clinical trial was designed to evaluative plasma concentration of dexamethasone achieved following injection of a freshly prepared mixture of 1.8 ml of 2% lignocaine with adrenaline (1:200000) and 1 ml (4 mg) dexamethasone [2.8 ml solution of twin mix] in the pterygomandibular space. The 30 candidates included for the trial were randomly split into three study groups (ten each)-(1) control group (C); (2) intramuscular group (IM); (3) intraspace group (IS). RESULTS: The mean plasma dexamethasone concentration at 30 min postinjection in group IM was 226.41 ± 48.67 ng/ml and for IS group it was 209.67 ± 88.13 ng/ml. Post hoc (Bonferroni-Holm test) intergroup comparison for plasma dexamethasone concentration (IM and IS) was found statistically insignificant (P = 0.605). CONCLUSION: Intraspace route of drug administration can be utilized to deliver dexamethasonized local anesthetics safely with predictable clinical effects in the patients requiring mandibular minor oral surgery under local anesthesia.
Asunto(s)
Adyuvantes Anestésicos/administración & dosificación , Anestésicos Locales/administración & dosificación , Dexametasona/administración & dosificación , Lidocaína/administración & dosificación , Nervio Mandibular , Bloqueo Nervioso/métodos , Adyuvantes Anestésicos/sangre , Adyuvantes Anestésicos/farmacocinética , Adulto , Anestésicos Locales/sangre , Anestésicos Locales/farmacocinética , Dexametasona/sangre , Dexametasona/farmacocinética , Método Doble Ciego , Femenino , Humanos , Inyecciones , Lidocaína/sangre , Lidocaína/farmacocinética , Masculino , Mandíbula , Músculos PterigoideosRESUMEN
RATIONALE: Gamma-hydroxybutyrate acid (GHB), a GABAB receptor agonist approved for treatment of narcolepsy, impairs driving ability, but little is known about doses and plasma concentrations associated with impairment and time course of recovery. OBJECTIVE: To assess effects of oral GHB (Xyrem®) upon driving as measured by a driving simulator, and to determine plasma concentrations associated with impairment and the time course of recovery. METHODS: Randomized, double-blind, two-arm crossover study, during which 16 participants received GHB 50 mg/kg orally or placebo. GHB blood samples were collected prior to and at 1, 3, and 6 h post dosing. Driving simulator sessions occurred immediately after blood sampling. RESULTS: Plasma GHB was not detectable at baseline or 6 h post dosing. Median GHB concentrations at 1 and 3 h were 83.1 mg/L (range 54-110) and 24.4 mg/L (range 7.2-49.7), respectively. Compared to placebo, at 1 h post GHB dosing, significant differences were seen for the life-threatening outcome collisions (p < 0.001) and off-road accidents (p = 0.018). Although driving was not faster, there was significantly more weaving and erratic driving with GHB as measured by speed deviation (p = 0.002) and lane position deviation (p = 0.004). No significant impairment regarding driving outcomes was found in the GHB group at 3 and 6 h post dose. CONCLUSION: GHB in doses used to treat narcolepsy resulted in severe driving impairment at 1 h post dosing. After 3 to 6 h, there was full recovery indicating that safe driving is expected the next morning after bedtime therapeutic GHB use in the absence of other substances.
Asunto(s)
Adyuvantes Anestésicos/administración & dosificación , Conducción de Automóvil/psicología , Simulación por Computador , Conducir bajo la Influencia/psicología , Oxibato de Sodio/administración & dosificación , Adyuvantes Anestésicos/efectos adversos , Adyuvantes Anestésicos/sangre , Administración Oral , Adulto , Estudios Cruzados , Método Doble Ciego , Femenino , Humanos , Masculino , Narcolepsia/sangre , Narcolepsia/tratamiento farmacológico , Oxibato de Sodio/efectos adversos , Oxibato de Sodio/sangreRESUMEN
The use of in vitro-in vivo extrapolation (IVIVE) techniques, mechanistically incorporated within physiologically based pharmacokinetic (PBPK) models, can harness in vitro drug data and enhance understanding of in vivo pharmacokinetics. This study's objective was to develop a user-friendly rat (250 g, male Sprague-Dawley) IVIVE-linked PBPK model. A 13-compartment PBPK model including mechanistic absorption models was developed, with required system data (anatomical, physiological, and relevant IVIVE scaling factors) collated from literature and analyzed. Overall, 178 system parameter values for the model are provided. This study also highlights gaps in available system data required for strain-specific rat PBPK model development. The model's functionality and performance were assessed using previous literature-sourced in vitro properties for diazepam, metoprolol, and midazolam. The results of simulations were compared against observed pharmacokinetic rat data. Predicted and observed concentration profiles in 10 tissues for diazepam after a single intravenous (i.v.) dose making use of either observed i.v. clearance (CLiv) or in vitro hepatocyte intrinsic clearance (CLint) for simulations generally led to good predictions in various tissue compartments. Overall, all i.v. plasma concentration profiles were successfully predicted. However, there were challenges in predicting oral plasma concentration profiles for metoprolol and midazolam, and the potential reasons and according solutions are discussed.
Asunto(s)
Adyuvantes Anestésicos/farmacocinética , Antiarrítmicos/farmacocinética , Anticonvulsivantes/farmacocinética , Diazepam/farmacocinética , Metoprolol/farmacocinética , Midazolam/farmacocinética , Adyuvantes Anestésicos/administración & dosificación , Adyuvantes Anestésicos/sangre , Adyuvantes Anestésicos/metabolismo , Administración Intravenosa , Animales , Antiarrítmicos/administración & dosificación , Antiarrítmicos/sangre , Antiarrítmicos/metabolismo , Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/sangre , Anticonvulsivantes/metabolismo , Simulación por Computador , Diazepam/administración & dosificación , Diazepam/sangre , Diazepam/metabolismo , Hepatocitos/metabolismo , Masculino , Tasa de Depuración Metabólica , Metoprolol/administración & dosificación , Metoprolol/sangre , Metoprolol/metabolismo , Midazolam/administración & dosificación , Midazolam/sangre , Midazolam/metabolismo , Modelos Biológicos , Ratas Sprague-DawleyAsunto(s)
Adyuvantes Anestésicos/envenenamiento , Oxibato de Sodio/envenenamiento , Accidentes Domésticos , Adyuvantes Anestésicos/sangre , Adyuvantes Anestésicos/orina , Preescolar , Escala de Coma de Glasgow , Humanos , Masculino , Respiración Artificial , Oxibato de Sodio/sangre , Oxibato de Sodio/orina , Inconsciencia/inducido químicamente , Vómitos/inducido químicamenteRESUMEN
A specific ultra-performance liquid chromatography tandem mass spectrometry method is described for the simultaneous determination of bupropion, metroprolol, midazolam, phenacetin, omeprazole and tolbutamide in rat plasma with diazepam as internal standard, which are the six probe drugs of the six cytochrome P450 isoforms CYP2B6, CYP2D6, CYP3A4, CYP1A2, CYP2C19 and CYP2C9. Plasma samples were protein precipitated with acetonitrile. The chromatographic separation was achieved using a UPLC® BEH C18 column (2.1 × 100 mm, 1.7 µm). The mobile phase consisted of acetonitrile and water (containing 0.1% formic acid) with gradient elution. The triple quadrupole mass spectrometric detection was operated by multiple reaction monitoring in positive electrospray ionization. The precisions were <13%, and the accuracy ranged from 93.3 to 110.4%. The extraction efficiency was >90.5%, and the matrix effects ranged from 84.3 to 114.2%. The calibration curves in plasma were linear in the range of 2-2000 ng/mL, with correlation coefficient (r(2) ) >0.995. The method was successfully applied to pharmacokinetic studies of the six probe drugs of the six CYP450 isoforms and used to evaluate the effects of erlotinib on the activities of CYP2B6, CYP2D6, CYP3A4, CYP1A2, CYP2C19 and CYP2C9 in rats. Erlotinib may inhibit the activity of CYP2B6 and CYP3A4, and may induce CYP2C9 of rats.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Sistema Enzimático del Citocromo P-450/metabolismo , Preparaciones Farmacéuticas/sangre , Espectrometría de Masas en Tándem/métodos , Adyuvantes Anestésicos/sangre , Analgésicos no Narcóticos/sangre , Animales , Antidepresivos de Segunda Generación/sangre , Bupropión/sangre , Clorhidrato de Erlotinib/farmacología , Hipoglucemiantes/sangre , Límite de Detección , Masculino , Midazolam/sangre , Omeprazol/sangre , Fenacetina/sangre , Inhibidores de Proteínas Quinasas/metabolismo , Inhibidores de la Bomba de Protones/sangre , Ratas , Ratas Sprague-Dawley , Tolbutamida/sangreRESUMEN
Electroporation (EP) is a physical method for the delivery of molecules into cells and tissues, including the skin. In this study, in order to control the degree of transdermal and topical drug delivery, EP at different amplitudes of electric pulses was evaluated. A new in vivo real-time monitoring system based on fluorescently labeled molecules was developed, for the quantification of transdermal and topical drug delivery. EP of the mouse skin was performed with new non-invasive multi-array electrodes, delivering different amplitudes of electric pulses ranging from 70 to 570 V, between the electrode pin pairs. Patches, soaked with 4 kDa fluorescein-isothiocyanate labeled dextran (FD), doxorubicin (DOX) or fentanyl (FEN), were applied to the skin before and after EP. The new monitoring system was developed based on the delivery of FD to and through the skin. FD relative quantity was determined with fluorescence microscopy imaging, in the treated region of the skin for topical delivery and in a segment of the mouse tail for transdermal delivery. The application of electric pulses for FD delivery resulted in enhanced transdermal delivery. Depending on the amplitude of electric pulses, it increased up to the amplitude of 360 V, and decreased at higher amplitudes (460 and 570 V). Topical delivery steadily enhanced with increasing the amplitude of the delivered electric pulses, being even higher than after tape stripping used as a positive control. The non-invasive monitoring of the delivery of DOX, a fluorescent chemotherapeutic drug, qualitatively and quantitatively confirmed the effects of EP at 360 and 570 V pulse amplitudes on topical and transdermal drug delivery. Delivery of FEN at 360 and 570 V pulse amplitudes verified the observed effects as obtained with FD and DOX, by the measured physiological responses of the mice as well as FEN plasma concentration. This study demonstrates that with the newly developed non-invasive multi-array electrodes and with the varying electric pulse amplitude, the amount of topical and transdermal drug delivery to the skin can be controlled. Furthermore, the newly developed monitoring system provides a tool for rapid real-time determination of both, transdermal and topical delivery, when the delivered molecule is fluorescent.
Asunto(s)
Adyuvantes Anestésicos/administración & dosificación , Antibióticos Antineoplásicos/administración & dosificación , Dextranos/administración & dosificación , Doxorrubicina/administración & dosificación , Sistemas de Liberación de Medicamentos/instrumentación , Electroporación/instrumentación , Fentanilo/administración & dosificación , Fluoresceína-5-Isotiocianato/análogos & derivados , Adyuvantes Anestésicos/sangre , Adyuvantes Anestésicos/farmacocinética , Administración Cutánea , Animales , Antibióticos Antineoplásicos/sangre , Antibióticos Antineoplásicos/farmacocinética , Dextranos/sangre , Dextranos/farmacocinética , Doxorrubicina/sangre , Doxorrubicina/farmacocinética , Femenino , Fluoresceína-5-Isotiocianato/administración & dosificación , Fluoresceína-5-Isotiocianato/farmacocinética , Ratones , Ratones Endogámicos BALB C , Piel/metabolismo , Absorción CutáneaRESUMEN
STUDY OBJECTIVES: Narcolepsy is caused by a selective loss of hypocretin neurons and is associated with obesity. Ghrelin and leptin interact with hypocretin neurons to influence energy homeostasis. Here, we evaluated whether human hypocretin deficiency, or the narcolepsy therapeutic agent sodium oxybate, alter the levels of these hormones. METHODS: Eight male, medication free, hypocretin deficient, narcolepsy with cataplexy patients, and 8 healthy controls matched for age, sex, body mass index (BMI), waisttohip ratio, and body fat percentage were assessed. Blood samples of total ghrelin and leptin were collected over 24 hours at 60 and 20-min intervals, respectively, during 2 study occasions: baseline, and during the last night of 5 consecutive nights of sodium oxybate administration (2 × 3.0 g/night). RESULTS: At baseline, mean 24-h total ghrelin (936 ± 142 vs. 949 ± 175 pg/mL, p = 0.873) and leptin (115 ± 5.0 vs. 79.0 ± 32 mg/L, p = 0.18) levels were not different between hypocretin deficient narcolepsy patients and controls. Furthermore, sodium oxybate did not significantly affect the plasma concentration of either one of these hormones. CONCLUSIONS: The increased BMI of narcolepsy patients is unlikely to be mediated by hypocretin deficiency-mediated alterations in total ghrelin or leptin levels. Thus, the effects of these hormones on hypocretin neurons may be mainly unidirectional. Although sodium oxybate may influence body weight, the underlying mechanism is unlikely to involve changes in total ghrelin or leptin secretion.
Asunto(s)
Ghrelina/sangre , Leptina/sangre , Narcolepsia/sangre , Narcolepsia/tratamiento farmacológico , Oxibato de Sodio/sangre , Oxibato de Sodio/uso terapéutico , Adyuvantes Anestésicos/sangre , Adyuvantes Anestésicos/uso terapéutico , Adulto , Composición Corporal/fisiología , Índice de Masa Corporal , Humanos , Masculino , Obesidad/sangreRESUMEN
In vivo drug interactions of the teratogen thalidomide with the model cytochrome P450 (P450) 3A substrate midazolam were investigated in mice with humanized livers. The clearance of midazolam (administered intravenously, 10 mg kg(-1)) in chimeric mice was enhanced by orally co-administered thalidomide (100 mg kg(-1)). A larger area under the curve of the major metabolite 1'-hydroxymidazolam (1.7-fold) was obtained with thalidomide because of the heterotropic cooperativity of human P450 3A enzymes. A larger area under the curve of the minor metabolite 4-hydroxymidazolam (3.5-fold) was seen with daily pretreatment with thalidomide for 3 days, presumably because of human P450 3A induction. These results demonstrate that livers of humanized mice mediate drug interactions of thalidomide and suggest interactions of therapeutic agents during therapies with thalidomide.
Asunto(s)
Adyuvantes Anestésicos/farmacología , Citocromo P-450 CYP3A/metabolismo , Inmunosupresores/farmacología , Hígado/metabolismo , Midazolam/farmacología , Teratógenos/farmacología , Talidomida/farmacología , Adyuvantes Anestésicos/administración & dosificación , Adyuvantes Anestésicos/sangre , Adyuvantes Anestésicos/metabolismo , Animales , Quimera/metabolismo , Interacciones Farmacológicas , Femenino , Humanos , Inmunosupresores/administración & dosificación , Inmunosupresores/metabolismo , Masculino , Ratones , Midazolam/administración & dosificación , Midazolam/sangre , Midazolam/metabolismo , Teratógenos/metabolismo , Talidomida/administración & dosificación , Talidomida/metabolismoRESUMEN
Fetal IM injection of fentanyl is frequently performed during ex utero intrapartum therapy (EXIT procedure). We quantified the concentration of fentanyl in umbilical vein blood. Thirteen samples from 13 subjects were analyzed. Medians and ranges are reported as follows. Weight of the newborn at delivery was 3000 g (2020-3715 g). The dose of fentanyl was 60 µg (45-65 µg). The time between IM administration of fentanyl and collection of the sample was 37 minutes (5-86 minutes). Fentanyl was detected in all of the samples, with a median serum concentration of 14.0 ng/mL (4.3-64.0 ng/mL).
Asunto(s)
Adyuvantes Anestésicos/sangre , Fentanilo/sangre , Sangre Fetal/metabolismo , Enfermedades Fetales/cirugía , Adyuvantes Anestésicos/administración & dosificación , Adyuvantes Anestésicos/farmacocinética , Peso al Nacer , Femenino , Fentanilo/administración & dosificación , Fentanilo/farmacocinética , Enfermedades Fetales/sangre , Edad Gestacional , Humanos , Recién Nacido , Inyecciones Intramusculares , Philadelphia , EmbarazoRESUMEN
OBJECTIVE: To determine the impact of three different target plasma concentrations of fentanyl on the minimum anaesthetic concentration (MAC) for isoflurane in the red-tailed hawk and the effects on the haemodynamic profile. STUDY DESIGN: Experimental study. ANIMAL POPULATION: Six healthy adult red-tailed hawks (Buteo jamaicensis) of unknown sex with body weights (mean ± SD) of 1.21 ± 0.15 kg. METHODS: This study was undertaken in two phases. In the first phase anaesthesia was induced with isoflurane in oxygen via facemask and maintained with isoflurane delivered in oxygen via a Bain circuit. Following instrumentation baseline determination of the MAC for isoflurane was made for each animal using the bracketing method and a supramaximal electrical stimulus. End-tidal isoflurane concentration (E'Iso) was then set at 0.75 × MAC and after an appropriate equilibration period a bolus of fentanyl (20 µg kg(-1)) was administered intravenously (IV) in order to determine the pharmacokinetics of fentanyl in the isoflurane-anaesthetized red-tailed hawk. During the second phase anaesthesia was induced in a similar manner and E'Iso was set at 0.75 × MAC for each individual. Fentanyl was infused IV to achieve target plasma concentrations between 8 and 32 ng mL(-1). At each fentanyl plasma concentration, the MAC for isoflurane and cardiovascular variables were determined. Data were analyzed by use of repeated-measures anova. RESULTS: Mean ± SD fentanyl plasma concentrations and isoflurane MACs were 0 ± 0, 8.51 ± 4, 14.85 ± 4.82 and 29.25 ± 11.52 ng mL(-1), and 2.05 ± 0.45%, 1.42 ± 0.53%, 1.14 ± 0.31% and 0.93 ± 0.32% for the target concentrations of 0, 8, 16 and 32 ng mL(-1), respectively. At these concentrations fentanyl significantly (p = 0.0016) decreased isoflurane MAC by 31%, 44% and 55%, respectively. Dose had no significant effect on heart rate, systolic, diastolic or mean arterial blood pressure. CONCLUSIONS AND CLINICAL RELEVANCE: Fentanyl produced a dose-related decrease of isoflurane MAC with minimal effects on measured cardiovascular parameters in red-tailed hawks.
Asunto(s)
Adyuvantes Anestésicos/farmacología , Anestesia por Inhalación/veterinaria , Anestésicos por Inhalación/farmacología , Presión Sanguínea/efectos de los fármacos , Fentanilo/farmacología , Halcones/fisiología , Frecuencia Cardíaca/efectos de los fármacos , Isoflurano/farmacología , Adyuvantes Anestésicos/administración & dosificación , Adyuvantes Anestésicos/sangre , Anestésicos por Inhalación/administración & dosificación , Animales , Análisis de los Gases de la Sangre , Temperatura Corporal/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Esquema de Medicación/veterinaria , Fentanilo/administración & dosificación , Fentanilo/sangre , Infusiones Intravenosas/veterinaria , Isoflurano/administración & dosificación , Movimiento/efectos de los fármacosRESUMEN
PURPOSE: Midazolam metabolic clearance to 1'-hydroxymidazolam is an accurate measure of CYP3A activity which requires extensive plasma and urine sampling. The objective of this study was to find a new limited sampling strategy (LSS) to predict midazolam metabolic clearance to 1'-hydroxymidazolam and subsequently CYP3A activity in an easy and reliable way, reducing costs and labour. METHODS: The development of this LSS is based on data from an in vivo drug-drug interaction study carried out in our clinical research unit. Various partial AUCs of midazolam were calculated and correlated with metabolic clearance of midazolam to 1'-hydroxymidazolam by non-linear regression. The correlation with highest r (2) values was chosen to predict the midazolam metabolic clearance. Statistical significance of this method was verified by calculating the 95% confidence interval of the differences (%) between predicted and measured metabolic clearance of midazolam to 1'-hydroxymidazolam. RESULTS: The midazolam partial AUC from 2 to 4 h after oral administration correlated best with metabolic clearance of midazolam to 1'-hydroxymidazolam with r (2) = 0.9816. This partial AUC comprised four midazolam concentrations at 2, 2.5, 3 and 4 h after oral administration of a midazolam solution. The 95% confidence interval of the differences between predicted metabolic clearance and measured metabolic clearance of midazolam to 1'-hydroxymidazolam was -0.97 to +13.2. CONCLUSION: The determination of the partial AUC using four plasma samples from 2 to 4 h after oral administration of a midazolam solution is proposed to be an easy and reliable CYP3A phenotyping measure which of course needs to be validated in prospective clinical trials.
Asunto(s)
Área Bajo la Curva , Citocromo P-450 CYP3A/metabolismo , Midazolam/sangre , Manejo de Especímenes/métodos , Adyuvantes Anestésicos/sangre , Administración Oral , Interacciones Farmacológicas , Humanos , Cómputos Matemáticos , Tasa de Depuración Metabólica , Midazolam/administración & dosificación , Midazolam/análogos & derivados , Midazolam/farmacocinética , Valor Predictivo de las Pruebas , Factores de TiempoRESUMEN
Two hundred and forty-seven serum samples which have been collected by police during roadside testing and have been found positive for amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA) and/or 3,4-methylenedioxyethamphetamine (MDE) were analyzed for gamma-hydroxybutyrate (GHB). Serum samples were spiked with deuterated GHB as internal standard and acetonitrile was added to achieve dilution and protein precipitation. Samples were analyzed with a LC-MS/MS system operated in the multiple reaction monitoring mode (MRM) using a TurboIonSpray source. Chromatographic separation was achieved using a Synergi Polar RP column applying a gradient elution with a runtime of 15 min. To differentiate between endogenous and exogenously administered GHB a cut-off concentration of 10 microg/mL was applied. Five samples exceeded this concentration and were found positive for GHB. These samples were only found positive for amphetamine but no other amphetamine derivatives were detected, while in three samples THC and in one sample cocaine, benzoylecgonine and ethanol were found.
Asunto(s)
Adyuvantes Anestésicos/sangre , Trastornos Relacionados con Anfetaminas/diagnóstico , Conducción de Automóvil/legislación & jurisprudencia , Oxibato de Sodio/sangre , Adolescente , Adulto , Anfetaminas/sangre , Depresores del Sistema Nervioso Central/sangre , Cocaína/análogos & derivados , Cocaína/sangre , Inhibidores de Captación de Dopamina/sangre , Etanol/sangre , Femenino , Toxicología Forense , Cromatografía de Gases y Espectrometría de Masas , Humanos , Masculino , Detección de Abuso de SustanciasRESUMEN
This study assessed the absolute and relative bioavailabilities and transmucosal and gastrointestinal absorbency of fentanyl buccal tablet (FBT) and oral transmucosal fentanyl citrate (OTFC). In a randomized crossover design, 26 healthy subjects received FBT 400 microg (transmucosal), FBT 800 microg (oral), OTFC 800 microg (transmucosal), and fentanyl 400 microg (intravenous). The transmucosal FBT had the highest absolute bioavailability (0.65) compared with the oral FBT (0.31) or transmucosal OTFC (0.47). More fentanyl was absorbed transmucosally from FBT than OTFC (48% vs 22%). Median t(max) values were shorter following the transmucosal FBT (47 minutes) than the oral FBT (90 minutes) or the transmucosal OTFC (91 minutes). Transmucosal administration of FBT compared with dose-normalized OTFC resulted in higher total systemic fentanyl exposure, higher early systemic exposure, and higher C(max). The rate and extent of fentanyl absorption were greater following administration of FBT compared to OTFC. An approximately 30% smaller dose of FBT achieved systemic exposures comparable to OTFC.
Asunto(s)
Adyuvantes Anestésicos/farmacocinética , Fentanilo/farmacocinética , Adyuvantes Anestésicos/administración & dosificación , Adyuvantes Anestésicos/sangre , Administración Bucal , Administración Oral , Adolescente , Adulto , Área Bajo la Curva , Disponibilidad Biológica , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Femenino , Fentanilo/administración & dosificación , Fentanilo/sangre , Tracto Gastrointestinal/metabolismo , Semivida , Humanos , Inyecciones Intravenosas , Absorción Intestinal , Masculino , Persona de Mediana Edad , Mucosa Bucal/metabolismo , Pacientes Desistentes del Tratamiento/estadística & datos numéricos , ComprimidosRESUMEN
BACKGROUND: Dexmedetomidine (DEX) has been shown to provide good perioperative haemodynamic stability with decreased intraoperative opioid requirements. It may have neural protective effects, and thus may be a suitable anaesthetic adjuvant to neurosurgical anaesthesia. METHODS: Fifty-four patients scheduled for elective surgery of supratentorial brain tumour were randomized to receive in a double-blind manner a continuous DEX infusion (plasma target concentration 0.2 or 0.4 ng ml(-1)) or placebo, beginning 20 min before anaesthesia and continuing until the start of skin closure. The DEX groups received fentanyl 2 microg kg(-1) at the induction of anaesthesia and before the start of operation, the placebo group 4 microg kg(-1), respectively. Anaesthesia was maintained with nitrous oxide in oxygen and isoflurane. RESULTS: The median times from the termination of N2O to extubation were 6 (3-27), 3 (0-20) and 4 (0-13) min in placebo, DEX-0.2 and DEX-0.4 groups, respectively (P<0.05 anova all-over effect). The median percentage of time points when systolic blood pressure was within more or less than 20% of the intraoperative mean was 72, 77 and 85, respectively (P<0.01), DEX-0.4 group differed significantly from the other groups. DEX blunted the tachycardic response to intubation (P<0.01) and the hypertensive response to extubation (P<0.01). DEX-0.4 group differed in the heart rate variability from placebo (93 vs 82%, P<0.01). CONCLUSIONS: DEX increased perioperative haemodynamic stability in patients undergoing brain tumour surgery. Compared with fentanyl, the trachea was extubated [corrected] faster without respiratory depression.
Asunto(s)
Adyuvantes Anestésicos/administración & dosificación , Neoplasias Encefálicas/cirugía , Dexmedetomidina/administración & dosificación , Adyuvantes Anestésicos/sangre , Adulto , Anciano , Anestesia por Inhalación , Presión Sanguínea/efectos de los fármacos , Dióxido de Carbono/sangre , Craneotomía , Dexmedetomidina/sangre , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Intubación Intratraqueal , Masculino , Persona de Mediana Edad , Presión Parcial , Cuidados Posoperatorios/métodosRESUMEN
BACKGROUND: Fentanyl decreases the minimum alveolar concentration (MAC) of inhaled anaesthetics and has been used clinically to reduce the requirements of other anaesthetic drugs in humans and small animals. We hypothesized that i.v. fentanyl would decrease the MAC of isoflurane in horses in a dose-dependent manner. METHODS: Following determination of baseline MAC of isoflurane, fentanyl was administered i.v. to target plasma concentrations of 1, 8 and 16 ng ml(-1). Each horse was randomly assigned two of three target concentrations administered in ascending order. Loading and infusion doses for each horse were determined from previously derived individual pharmacokinetic values. Isoflurane MAC determination began 45 min after fentanyl administration at each target fentanyl concentration. Venous blood was collected at fixed intervals during the infusion for measurement of plasma fentanyl concentrations. RESULTS: Mean actual fentanyl plasma concentrations were 0 (baseline), and 0.72 (SD 0.26), 8.43 (3.22), and 13.31 (6.66) ng ml(-1) for the target concentrations of 1, 8 and 16 ng ml(-1), respectively. The corresponding isoflurane MAC values were a baseline of 1.57 (0.23), and 1.51 (0.24), 1.41 (0.23) and 1.37 (0.09)%, respectively. The fentanyl concentrations of 0.72 and 8.43 ng ml(-1) did not significantly alter the MAC of isoflurane, but an 18 (7)% ISO-MAC reduction was observed at the 13.31 ng ml(-1) concentration. CONCLUSIONS: These results cautiously encourage further study of fentanyl as an opioid anaesthetic adjunct to inhalant anaesthesia in horses.
Asunto(s)
Anestésicos por Inhalación/análisis , Anestésicos Intravenosos/administración & dosificación , Fentanilo/administración & dosificación , Caballos , Isoflurano/análisis , Alveolos Pulmonares/química , Adyuvantes Anestésicos/administración & dosificación , Adyuvantes Anestésicos/sangre , Analgésicos Opioides/administración & dosificación , Analgésicos Opioides/sangre , Anestesia General/métodos , Anestesia General/veterinaria , Anestésicos Intravenosos/sangre , Animales , Esquema de Medicación , Interacciones Farmacológicas , Femenino , Fentanilo/sangre , Caballos/sangre , Infusiones Intravenosas/veterinaria , MasculinoRESUMEN
A sensitive enzyme-linked immunosorbent assay (ELISA) was developed for the detection of fentanyl in serum and urine. The ELISA used an indirect competitive method produced by coating the plate with thyroglobulin conjugated with fentanyl hapten. Antibodies against fentanyl-hemocyanin were detected by a goat-anti-rabbit antibody conjugated with alkaline phosphatase. Calibration standard curves ranged from 0.5ng/ml to 50mug/ml (IC(50)=10ng/ml), and the limits of detection were 0.5 and 1.0ng/ml for serum and urine, respectively. The intra- and inter-assay variations were less than 8% and 10%, respectively. The antibody produced against fentanyl completely cross-reacted with p-fluorofentanyl, thienylfentanyl and 3-methylthienylfentanyl, cross-reacted highly with carfentanil (85%), but was considered non-cross-reactive with alpha-methylfentanyl (5%), sufentanil (<1%), alfentanil (<1%) and lofentanil (<1%). Nano-sized iron oxide magnetic particles coated with the developed fentanyl antibody were capable of specific binding and releasing of fentanyl from urine samples. This enabled the drug to be effectively pre-concentrated and decreased the limit of detection by approximately one order of magnitude. The analytical background noise was significantly reduced to enable fentanyl detection at concentrations originally below chromatographic limit of detection. The change of platform for antibody binding with nanoparticles demonstrated a novel use of antibodies for sample preparation and should facilitate drug screening by traditional ELISA.
Asunto(s)
Adyuvantes Anestésicos/orina , Anticuerpos/metabolismo , Fentanilo/orina , Adyuvantes Anestésicos/sangre , Adyuvantes Anestésicos/metabolismo , Animales , Antibacterianos/orina , Reacciones Cruzadas , Electroforesis Capilar/métodos , Ensayo de Inmunoadsorción Enzimática/métodos , Fentanilo/análogos & derivados , Fentanilo/metabolismo , Caballos , Nanoestructuras , ConejosRESUMEN
OBJECTIVE: There is only limited knowledge on the pharmacokinetics of midazolam and its active metabolites in potential organ donors. Before establishing the diagnosis of brain death, drugs interfering with the neurological assessment have to be washed out. National guidelines advise a waiting time of 12 hours. The aim of our study was to evaluate whether it is sufficient to rely on a calculated waiting time. METHODS: As examples of typical pharmacokinetics of midazolam and its metabolites, we followed the concentration over time in four potential organ donors with immunoassays and high-performance liquid chromatography (HPLC). RESULTS AND CONCLUSIONS: In each of the 4 patients studied, the elimination of midazolam and/or midazolam metabolites was delayed. As long as brain death diagnosis requires that drugs interfering with the clinical assessment must be at levels below the therapeutic range, monitoring of midazolam and metabolites appears mandatory.
Asunto(s)
Muerte Encefálica/diagnóstico , Midazolam/farmacocinética , Donantes de Tejidos , Adyuvantes Anestésicos/sangre , Adyuvantes Anestésicos/farmacocinética , Adulto , Anestésicos Intravenosos/sangre , Anestésicos Intravenosos/farmacocinética , Cromatografía Líquida de Alta Presión , Glucurónidos/sangre , Humanos , Hipnóticos y Sedantes/sangre , Hipnóticos y Sedantes/farmacocinética , Midazolam/análogos & derivados , Midazolam/sangre , Persona de Mediana EdadRESUMEN
Benefits from an antihypoxic agent (sodium oxibutyrate) and normal pressure hyperoxia to the lipid composition of erythrocyte membranes and blood plasma were assessed in 9 subjects on the thirtieth day of head-down tilting at -8(0). The greatest variations in HDT occurred in polyunsaturated fatty acids in erythrocyte membranes. After infusion of sodium oxibutyrate a marked reduction in polyunsaturated fatty acids was mainly in consequence of expressed decreases in linoleic and, particularly, arachidonic acids. However, ensuing hyperoxic treatment led to their steady rise. Sequential sodium oxibutyrate infusion to the tilted subjects breathing air and then exposed to normal pressure hyperoxia seemed to have compensated, as judged by the fatty acids in erythrocyte membranes, for the activity of free radical oxidation in hypoperfusated regional tissues.